Buy Glucagen Hypokit vials 1 mg
  • Buy Glucagen Hypokit vials 1 mg

Glucagen® [Glucagon]

Novo Nordisk
70 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$43.19
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

GlucaGen 1 mg HypoCyte contains a human genetic glucagon, a protein-peptide hormone, a physiological insulin antagonist involved in the regulation of carbohydrate metabolism. Glucagon enhances the breakdown of glycogen in the liver to glucose-6-phosphate (glucogenolysis), as a result of which the concentration of glucose in the blood rises. Glucagon is not effective in treating patients in whose liver glycogen stores are depleted. For this reason, glucagon is ineffective or not effective at all in treating patients on an empty stomach or patients with adrenal insufficiency, chronic hypoglycemia, or hypoglycemia caused by alcohol intake. Unlike adrenaline, glucagon has no effect on muscle phosphorylase and therefore cannot promote the transfer of carbohydrates from skeletal muscles richer in glycogen stores. Glucagon stimulates the release of catecholamines. In the presence of a pheochromocytoma, glucagon can trigger a tumor to release a large number of catecholamines, which cause a sharp increase in blood pressure. Glucagon reduces the contractile ability of the smooth muscles of the gastrointestinal tract. The action of the drug begins 1 minute after intravenous injection, the duration of the drug is 5-20 minutes, depending on the dose and organ. In the treatment of severe hypoglycemia, the effect of glucagon on blood glucose is usually observed within 10 minutes.

Indications

Severe hypoglycemic states (low blood glucose) that occur in diabetic patients after insulin injection or taking pills of hypoglycemic drugs.

Composition

Active ingredient: Glucagon hydrochloride genetically engineered - 1 mg (corresponding to 1 IU).

No customer reviews for the moment.

Write your review

Write your review

Glucagen® [Glucagon]

Dosage and Administration

To prepare the injection solution, 1 mg (1 ME) of the lyophilisate is dissolved in 1 ml of solvent. The resulting solution can be injected subcutaneously, intramuscularly or intravenously. In this dosage form, the drug Glucagen Hypokit is administered subcutaneously or intramuscularly. Administration of the drug by medical personnel Enter 1 mg (for adults and children weighing more than 25 kg or 6-8 years) or 0.5 mg (for children weighing less than 25 kg or less than 6-8 years) subcutaneously, intramuscularly or intravenously. The patient usually regains consciousness within 10 minutes after drug administration. After the patient regains consciousness, he needs to be given carbohydrate-rich food to prevent the recurrence of hypoglycemia. If the patient does not regain consciousness within 10 minutes, he needs to introduce intravenous glucose. Drug Administration to a Patient by a Relative (s) Relatives or close friends of a patient with diabetes mellitus should know that if he develops a severe hypoglycemic reaction, he needs medical assistance. If a patient with diabetes has developed severe hypoglycemia, and he is not able to eat sugar, relatives or friends should give him an injection of the drug GlucaGen 1 mg HypoKit. Enter 1 mg (for adults and children weighing more than 25 kg) or 0.5 mg (for children weighing less than 25 kg or less than 6-8 years old) subcutaneously or in the upper outer part of the thigh muscles. The patient usually regains consciousness within 10 minutes after drug administration. After the patient regains consciousness, he must be given sugar to prevent the recurrence of hypoglycemia. All patients with severe hypoglycemia need medical attention.

Adverse reactions

On the part of the digestive tract: nausea, vomiting.

Since the cardiovascular system and blood (hematopoiesis, hemostasis): transient increase in blood pressure, tachycardia.

Allergic reactions: skin rash and itching, urticaria, bronchospasm, anaphylactic shock.

Other: hypokalemia, dehydration.

Contraindications

Increased individual sensitivity to glucagon or any other component of the drug; hyperglycemia; pheochromocytoma.

Drug interactions

On the background of beta-adrenergic blockers, administration of the drug GlucaGen 1 mg HypoCyte can lead to severe tachycardia and an increase in blood pressure. Insulin: The action of glucagon is the opposite of insulin (insulin is an antagonist of glucagon). Indomethacin: when used together, glucagon may lose its ability to increase blood glucose and even cause hypoglycemia. Warfarin: when used together, glucagon can enhance the effect of warfarin anticoagulant.

Pregnancy and Lactation

GlucaGen does not pass through the human placental barrier and can be used to treat severe hypoglycemia during pregnancy. When prescribing the drug during the breastfeeding period, there is no risk for the child.

Special instructions

After the introduction of the drug GlucaGen 1 mg HypoKit, it is necessary to control the glucose content in the blood plasma. GlucaGen 1 mg HypoCyg has a hyperglycemic effect only in the presence of glycogen in the liver, so it will be ineffective in starving patients, in patients with adrenal insufficiency and chronic hypoglycemia, as well as if hypoglycemia is caused by excessive alcohol consumption. Care should be taken when using the drug Glucagen Hypokit in patients with insulinoma or glucagonoma. A patient with diabetes should strictly adhere to medical recommendations aimed at preventing hypoglycemic conditions. Do not use the solution if it looks like a gel, or if the powder is not completely dissolved. The bottle has a protective, heat-resistant plastic cap with a color code. In order to dissolve the powder of the drug GlucaGen 1 mg HypoKit, you must remove the plastic cap. If it is lost or missing upon purchase, return it to the pharmacy.

Overdosage

In case of overdose of the drug GlucaGen 1 mg HypoKit, nausea, vomiting, diarrhea, hypokalemia, tachycardia, increased blood pressure may occur. Symptomatic treatment. Requires constant monitoring of the level of potassium and, if necessary, its correction. The use of forced diuresis and hemodialysis is ineffective. In the event of vomiting, rehydration and potassium loss replacement.

Studies and clinical trials of Glucagon (Click to expand)

  1. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to α-glucosidase inhibition (acarbose) in Type 2 diabetic patients
  2. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system
  3. Glucagon and glucagon-like peptide signaling pathways in the liver of two fish species, the American eel and the black bullhead
  4. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia
  5. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes
  6. Glucagon-like peptide-1 does not mediate amylase release from AR42J cells
  7. Effect of Mobile Phase Composition on Selectivity in Preparative Hydrophobic Interaction Chromatographic Purification of Glucagon
  8. Experimental model for optimization of hydrophobic interaction: chromatographic purification of glucagon
  9. Inositolphosphoglycans possibly mediate the effects of glucagon-like peptide-1(7-36)amide on rat liver and adipose tissue
  10. Activation and glucagon regulation of mitogen-activated protein kinases (MAPK) by insulin and epidermal growth factor in cultured rat and human hepatocytes
  11. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–36 amide) (GLP-1)
  12. Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes
  13. Secretion of various endocrine substances by acth-secreting tumors—gastrin, melanotropin, norepinephrine, serotonin, parathormone, vasopressin, glucagon
  14. Insulin and glucagon secretion by renal adenocarcinoma
  15. Large glucagon-like immunoreactivity in a primary ovarian carcinoid
  16. Metastatic islet cell tumor with ACTH, gastrin, and glucagon secretion clinical and pathologic studies with multiple therapies
  17. Glucagon-induced self-association of recombinant proteins in Escherichia coli and affinity purification using a fragment of glucagon receptor
  18. Effects of prolonged exposure to pancreatic glucagon on the function, antigenicity and survival of isolated human islets
  19. Immunohistochemical localization of somatostatin, insulin and glucagon in the principal islets of the anglerfish (Lophius americanus) and the channel catfish (Ictalurus punctata)
  20. Glucagon levels in pancreatic extracts and plasma of the lizard
  21. Functional differentiation of the chick endocrine pancreas. II. The alpha cells and glucagon
  22. Effects of glucagon on hepatic glycogen and smooth endoplasmic reticulum
  23. Immunocytochemical identification of cells containing insulin, glucagon, somatostatin, and pancreatic polypetide in the islets of langerhans of the guinea pig pancreas with light and electron microscopy
  24. Receptor-mediated endocytosis of glucagon in isolated mouse hepatocytes

Customers who bought this product also bought:

8 other products in the same category:

arrow_upward